ATE328074T1 - Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten - Google Patents

Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten

Info

Publication number
ATE328074T1
ATE328074T1 AT00910916T AT00910916T ATE328074T1 AT E328074 T1 ATE328074 T1 AT E328074T1 AT 00910916 T AT00910916 T AT 00910916T AT 00910916 T AT00910916 T AT 00910916T AT E328074 T1 ATE328074 T1 AT E328074T1
Authority
AT
Austria
Prior art keywords
secondary structure
antisense sequence
oligonucleotide
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT00910916T
Other languages
English (en)
Inventor
Claude Malvy
Andrei Maksimenko
Valerie Helin
Marina Gottikh
Original Assignee
Bioalliance Pharma Sa
Centre Nat Rech Scient
Inst Gustave Roussy Igr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma Sa, Centre Nat Rech Scient, Inst Gustave Roussy Igr filed Critical Bioalliance Pharma Sa
Application granted granted Critical
Publication of ATE328074T1 publication Critical patent/ATE328074T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT00910916T 1999-03-09 2000-03-09 Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten ATE328074T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902921A FR2790757B1 (fr) 1999-03-09 1999-03-09 Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
ATE328074T1 true ATE328074T1 (de) 2006-06-15

Family

ID=9542992

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910916T ATE328074T1 (de) 1999-03-09 2000-03-09 Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten

Country Status (12)

Country Link
US (1) US7022832B2 (de)
EP (1) EP1175489B1 (de)
JP (1) JP2004500018A (de)
AT (1) ATE328074T1 (de)
AU (1) AU3295700A (de)
CA (1) CA2363255A1 (de)
DE (1) DE60028367T2 (de)
DK (1) DK1175489T3 (de)
ES (1) ES2265916T3 (de)
FR (1) FR2790757B1 (de)
PT (1) PT1175489E (de)
WO (1) WO2000053745A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921821A1 (en) 2001-07-12 2003-01-23 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
EP1838875A4 (de) * 2004-12-30 2010-08-25 Todd M Hauser Zusammensetzungen und verfahren zur modulation der genexpression unter verwendung selbstgeschützer oligonukleotide
US8093369B2 (en) * 2005-10-11 2012-01-10 Ben Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of VDAC1 and uses thereof
WO2008039937A2 (en) * 2006-09-27 2008-04-03 Novarx Blocking of gene expression in eukaryotic cells
US7645578B2 (en) * 2006-10-31 2010-01-12 Agilent Technologies, Inc. Cleavage of RNA at redundant sites
US9279127B2 (en) * 2006-11-01 2016-03-08 The Medical Research Fund At The Tel-Aviv Sourasky Medical Center Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
US8283460B2 (en) * 2008-10-15 2012-10-09 Somagenics, Inc. Short hairpin RNAs for inhibition of gene expression
WO2010047216A1 (ja) * 2008-10-23 2010-04-29 国立大学法人 東京大学 microRNAの機能阻害法
EP2454371B1 (de) 2009-07-13 2021-01-20 Somagenics, Inc. Chemische modifikation kleiner haarnadel-rnas zur genexpressionshemmung
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
KR101849798B1 (ko) * 2010-07-08 2018-04-17 가부시키가이샤 보낙 유전자 발현 제어를 위한 일본쇄 핵산 분자
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
WO2013180038A1 (ja) 2012-05-26 2013-12-05 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
EP2970965A2 (de) * 2013-03-15 2016-01-20 Pronai Therapeutics, Inc. Dnai zur modulation von genen
JP6486836B2 (ja) 2013-12-26 2019-03-20 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
AU2014370829B2 (en) 2013-12-27 2021-03-11 Bonac Corporation Artificial match-type miRNA for controlling gene expression and use therefor
SG11201705223XA (en) 2014-12-27 2017-07-28 Bonac Corp NATURALLY OCCURING miRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME
CN108064289A (zh) 2015-03-27 2018-05-22 株式会社博纳克 具有递送功能和基因表达调控能力的单链核酸分子
CN116262919A (zh) 2021-12-14 2023-06-16 成都凌泰氪生物技术有限公司 一种基于miRNA-2911的核酸分子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2139319A1 (en) * 1992-07-02 1994-01-20 Sudhir Agrawal Self-stabilized oligonucleotides as therapeutic agents
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
US5631148A (en) * 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement

Also Published As

Publication number Publication date
PT1175489E (pt) 2006-10-31
CA2363255A1 (fr) 2000-09-14
JP2004500018A (ja) 2004-01-08
AU3295700A (en) 2000-09-28
EP1175489B1 (de) 2006-05-31
FR2790757A1 (fr) 2000-09-15
FR2790757B1 (fr) 2003-08-01
DE60028367D1 (de) 2006-07-06
ES2265916T3 (es) 2007-03-01
US20020156261A1 (en) 2002-10-24
DK1175489T3 (da) 2006-10-02
US7022832B2 (en) 2006-04-04
WO2000053745A9 (fr) 2001-11-08
EP1175489A1 (de) 2002-01-30
WO2000053745A1 (fr) 2000-09-14
DE60028367T2 (de) 2007-02-08

Similar Documents

Publication Publication Date Title
ATE328074T1 (de) Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
EP1798285B1 (de) Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE60325016D1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
WO2007143316A3 (en) Compounds and methods for modulating expression of sglt2
DE69432315D1 (de) ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
BR0011347A (pt) Preparações e formas de administração compreendendo um composto ativo de ácido instável
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
WO2005055948A3 (en) Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders
EP1362600A4 (de) Pharmazeutische zusammensetzungen mit einem decoy und verfahren zu ihrer verwendung
DE69017983D1 (de) Anti-sens Nukleotidsequenz, anti-RNS des alpha-TNFS, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel und pharmazeutische Präparate davon.
WO2003101394A3 (en) Defensins: use as antiviral agents
WO2005039480A8 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
EP1385948A4 (de) Nukleinsäuren zur hemmung der expression von hairless-protein und verfahren zur verwendung davon
DE60117572T2 (de) Inhibitoren der Reversen Transkriptase von HIV aus tRNA
IL164674A (en) Catalytic deoxyribonucleic acid that cleaves pai-1 and uses thereof
WO1997004087A1 (de) Ribozyme zur selektiven hemmung der expression von genen von mhc-allelen und diese enthaltende arzneimittel
DE50303606D1 (de) Decoy-oligonukleotid-hemmung der cd40-expression
EP2527442A3 (de) Verbindungen und Verfahren zur Modulation von Genexpression
WO2004035759A3 (en) Inhibitory oligonucleotides targeted to matrix metalloproteinase-9
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175489

Country of ref document: EP

REN Ceased due to non-payment of the annual fee